Price alert —
Sign in to get a one-time email the moment PSNL crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · PSNL
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
No quarterly financials available.
Compare PSNL vs peers
Line PSNL up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with PSNL
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 0 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
No earnings history available.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| PSNL ★ | $1B | — | -14.3 | 21.1 | -13.1 | 5.3 | 13.7% | -24.9% | — | -3.12% |
| LLY | $1,036B | 41.4 | 25.9 | — | 30.0 | 33.3 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $394B | 32.7 | 19.3 | 0.9 | 18.1 | 3.8 | 19.5% | 0.4% | 61.5% | 5.78% |
| JNJ | $613B | 29.6 | 19.8 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $316B | 36.1 | 13.3 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.44% |
| ABBV | $451B | 124.5 | 15.7 | 7.2 | 17.2 | -67.7 | 72.0% | 12.4% | -46.2% | 4.62% |
| PFE | $142B | 19.0 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.71% |
| TMO | $195B | 28.9 | 19.3 | — | 20.8 | 3.8 | 40.9% | 6.2% | 11.3% | 2.83% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 57.43%
| Holder | Shares | % out |
|---|---|---|
| Merck & Co., Inc. | 14,044,943 | 13.41% |
| Lightspeed Management Company, L.L.C | 8,160,734 | 7.79% |
| ARK Investment Management, LLC | 7,944,112 | 7.59% |
| Ameriprise Financial, Inc. | 7,592,807 | 7.25% |
| Blackrock Inc. | 5,389,885 | 5.15% |
| T. Rowe Price Investment Management, | 4,758,091 | 4.54% |
| Aberdeen Group plc | 3,488,308 | 3.33% |
| Deep Track Capital, Lp | 3,000,000 | 2.86% |
| AIGH Capital Management LLC | 2,900,000 | 2.77% |
| Vanguard Capital Management LLC | 2,868,463 | 2.74% |
Insider activity · 90d
0 buys / 4 sells · ratio 0.0 · Finnhub
- Hall Christopher M M 0
- Hall Christopher M M 133,333
- Hall Christopher M SELL 235,986 @ $15.08
- Hall Christopher M M 335,986 @ $1.61
- Hall Christopher M M 200,000
- Hall Christopher M SELL 235,986 @ $13.15
- Hall Christopher M M 335,986 @ $1.61
- Tachibana Aaron M 7,471
- Tachibana Aaron M 0
- Tachibana Aaron SELL 198,833 @ $13.18
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-20 | 8-K | view · |
| 8-K | 2026-07-20 | 8-K | view · |
| 4 | 2026-07-15 | Insider transaction (Form 4) | view · |
| 4 | 2026-07-09 | Insider transaction (Form 4) | view · |
| 4 | 2026-06-29 | Insider transaction (Form 4) | view · |
| 4 | 2026-06-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-06-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-06-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-29 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-29 | Insider transaction (Form 4) | view · |
| 8-K | 2026-05-20 | 8-K | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 8-K | 2026-05-13 | 8-K | view · |
| 8-K | 2026-05-13 | 8-K | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| DEF 14A | 2026-04-02 | DEF 14A | view · |
| 4 | 2026-03-17 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-17 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-17 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-17 | Insider transaction (Form 4) | view · |
| 8-K | 2026-03-17 | 8-K | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 8-K | 2026-02-26 | 8-K | view · |
| 4 | 2026-02-25 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-25 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-25 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-25 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-13 | 4 | view · |
| 4 | 2026-01-23 | Insider transaction (Form 4) | view · |
| 8-K | 2026-01-08 | 8-K | view · |
| 8-K | 2025-11-28 | 8-K | view · |
| 4 | 2025-11-28 | Insider transaction (Form 4) | view · |
| 8-K | 2025-11-25 | 8-K | view · |
| 8-K | 2025-11-10 | 8-K | view · |
| 4 | 2025-11-05 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-11-04 | 10-Q | view · |
| 8-K | 2025-11-04 | 8-K | view · |
| 8-K | 2025-08-22 | 8-K | view · |
| 8-K | 2025-08-05 | 8-K | view · |
| 10-Q | 2025-08-05 | 10-Q | view · |
| 4 | 2025-07-30 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-30 | Insider transaction (Form 4) | view · |
| 8-K | 2025-07-09 | 8-K | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 4 | 2025-05-20 | Insider transaction (Form 4) | view · |
| 8-K | 2025-05-19 | 8-K | view · |
| 10-Q | 2025-05-06 | 10-Q | view · |
About PSNL
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer …
Options picks · PSNL
ITM + OTM ideas from the latest scanLoading…
Congress trades · PSNL
STOCK Act disclosuresLoading…
SEC filings & insiders · PSNL
EDGAR · liveLoading…
Holders · PSNL
Institutions & insider activityLoading…